InDex Pharmaceuticals Holding AB
STO:FLERIE
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| SE |
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
2.7B SEK |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
965.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
594B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
105.9B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
InDex Pharmaceuticals Holding AB
Glance View
InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
